Skip to main content

Table 2 Gross and histopathological analysis of TBL in lung and pulmonary lymphoid nodes

From: Evaluation of the immunogenicity and efficacy of BCG and MTBVAC vaccines using a natural transmission model of tuberculosis

  Control BCG MTBVAC
Lung
 Median no. of lobes affected 3.5 (IQR 1–4) 1 (IQR 0.8–1)* 2 (IQR 1–2.5)
 Median score 4 (IQR 1–5.8) 1 (IQR 0.8–1.3)* 2 (IQR 1–4)
 No. animals with TBL 10/11 (83.3%)b 3/14 (21.4%)* 8/13 (61.5%)
 Development stage of granulomas
  I 0/11 (0%) 0/14 (0%) 0/13 (0%)
  II 1/11 (9.1%) 0/14 (0%) 3/13 (23.1%)
  III 2/11 (18.2%) 0/14 (0%) 0/13 (0%)
  IV 7/11 (63.6%) 3/14 (21.4%)* 5/13 (38.5%)
 Mean of MNGCsa 7 (± 8.1) 1.6 (± 3.7)* 5.1 (± 8)
 No. animals with satellite granulomas 0/11 (0%) 1/14 (7.1%) 0/13 (0%)
Pulmonary LNs
 Median score 6.5 (IQR 4.3–9.8) 2 (IQR 1–3.3)* 2 (IQR 2–4)*
 No. animals with TBL 11/11 (100%)b 8/14 (57.1%)* 10/13 (76.9%)
 Development stage of granulomas
  I 0/11 (0%) 0/14 (0%) 1/13 (7.7%)
  II 1/11 (9.1%) 0/14 (0%) 0/13 (0%)
  III 1/11 (9.1%) 0/14 (0%) 0/13 (0%)
  IV 9/11 (81.8%) 8/14 (57.1%) 9/13 (69.2%)
 Mean of MNGCs 10.7 (± 6.9) 3.71 (± 5.52)* 9.1 (± 11.7)
 No. animals with satellite granulomas 5/11 (45.5%) 1/14 (7.1%) 4/13 (30.8%)
  1. IQR, interquartile range; MNGC, multinucleated giant cells; TBL, tuberculous lesion.
  2. * Statistically significant difference with regard to the control group (p ≤ 0.05).
  3. aMNGCs per animal (mean of three microscopic fields 400×).
  4. bLung and pulmonary samples from one animal were not well fixed in formalin and could not be assessed for histopathology.